Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Two-Part, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-050 Administered to Healthy, Postmenopausal Women.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elritercept (Primary)
Indications Anaemia; Duchenne muscular dystrophy; Facioscapulohumeral muscular dystrophy; Thrombocytopenia
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Keros Therapeutics

21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
12 Jun 2020 According to a Keros Therapeutics media release, data from this study was presented at the 25th Annual Congress of European Hematology Association (EHA), held as a virtual event from June 11-21, 2020.
12 Jun 2020 Results published in the Keros Therapeutics media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com